MRPL23-AS1: A Potential Drug Target and Biomarker (G100133545)

Target Name: MRPL23-AS1

NCBI ID: G100133545

MRPL23-AS1

Other Name(s): TP53LC10 | MRPL23 antisense RNA 1

MRPL23-AS1: A Potential Drug Target and Biomarker

Mutations in the Myeloid Growth Factor Receptor (MGR) gene have been linked to various myeloproliferative neoplasms, including acute myeloid leukemia, myelodysplastic syndromes, and myeloma. The MGR gene is a key regulator of hematopoietic stem cell proliferation and maturation, and its mutational variants have been implicated in the development and progression of these diseases. One of the most promising lead compounds for the treatment of these conditions is MRPL23-AS1, a potential drug target and biomarker.

MRPL23-AS1 is a gene that encodes a protein known as MGR23, which is a critical regulator of hematopoietic stem cell proliferation and differentiation. The MGR23 protein plays a vital role in the development and maintenance of normal hematopoietic stem cells, and is also involved in the regulation of granulocyte development and function. MGR23 has been shown to be highly expressed in various types of leukemia, including acute myeloid leukemia, and has been linked to the development of these conditions.

The potential utility of MRPL23-AS1 as a drug target is based on its role in the regulation of hematopoietic stem cell proliferation and maturation. By targeting the MGR23 protein, researchers have been able to block its activity and prevent the development of leukemia. In addition, MRPL23-AS1 has also been shown to play a role in the regulation of granulocyte development and function, which could make it an attractive target for the treatment of myelodysplastic syndromes and other myeloproliferative neoplasms.

The potential utility of MRPL23-AS1 as a biomarker is based on its ability to serve as a potential therapeutic target. By blocking the activity of MGR23, researchers have been able to reduce the number of leukemia-initiating cells and increase the percentage of normal hematopoietic stem cells. This has led to an increase in the overall sensitivity of the leukemia cells to chemotherapy, as well as a reduction in the risk of relapse.

In addition, MRPL23-AS1 has also been shown to have potential as a biomarker for the diagnosis and prognosis of acute myeloid leukemia. By analyzing the expression levels of MGR23 in leukemia cells, researchers have been able to determine the overall sensitivity of the cells to different treatment options and to identify potential biomarkers for the disease.

The identification of MRPL23-AS1 as a potential drug target and biomarker has important implications for the treatment of various myeloproliferative neoplasms, including acute myeloid leukemia. By targeting the MGR23 protein, researchers have been able to block its activity and prevent the development of leukemia, as well as to identify potential biomarkers for the disease. Further research is needed to determine the efficacy and safety of MRPL23-AS1 as a potential drug and to develop it as a biomarker for the diagnosis and prognosis of acute myeloid leukemia and other myeloproliferative neoplasms.

Protein Name: MRPL23 Antisense RNA 1

The "MRPL23-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL23-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets